Pacira Pharmaceuticals Stock Analysis

Pacira Stock Analysis Notes

About 99.0% of the company shares are owned by institutional investors. The company has price-to-book ratio of 1.43. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Pacira Pharmaceuticals had not issued any dividends in recent years. Pacira BioSciences, Inc. provides non-opioid pain management and regenerative health solutions for healthcare practitioners and their patients in the United States. Pacira BioSciences, Inc. was incorporated in 2006 and is headquartered in Tampa, Florida. Pacira Pharm operates under Drug ManufacturersSpecialty Generic classification in the United States and is traded on NASDAQ Exchange. It employs 697 people. To find out more about Pacira Pharmaceuticals contact David Stack at 813 553 6680 or learn more at https://www.pacira.com.

Pacira Pharmaceuticals Investment Alerts

Pacira Pharmaceuticals Upcoming and Recent Events

Pacira Largest EPS Surprises

View All Earnings Estimates

Pacira Stock Institutional Investors

Note, although Pacira Pharmaceuticals' institutional investors appear to be way more sophisticated than retail investors, it remains unclear if professional active investment managers can reliably enhance risk-adjusted returns by an amount that exceeds fees and expenses.

Pacira Market Capitalization

The company currently falls under 'Mid-Cap' category with a current market capitalization of 1.25 B. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Pacira Pharmaceuticals's market, we take the total number of its shares issued and multiply it by Pacira Pharmaceuticals's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and those looking for more risk prefer small-cap and mid-cap equities.

Pacira Profitablity

The company has Profit Margin (PM) of 0.06 %, which maeans that even a very small decline in it revenue will erase profits resulting in a net loss. This is way below average. Similarly, it shows Operating Margin (OM) of 0.19 %, which suggests for every 100 dollars of sales, it generated a net operating income of $0.19.

Management Efficiency

Pacira Pharmaceuticals has return on total asset (ROA) of 0.0335 % which means that it generated a profit of $0.0335 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.051 %, meaning that it created $0.051 on every $100 dollars invested by stockholders. Pacira Pharmaceuticals' management efficiency ratios could be used to measure how well Pacira Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. Return On Tangible Assets is likely to rise to 0.05 in 2024. Return On Capital Employed is likely to rise to 0.06 in 2024. At this time, Pacira Pharmaceuticals' Total Assets are fairly stable compared to the past year. Non Current Assets Total is likely to rise to about 1.1 B in 2024, whereas Other Assets are likely to drop 0.95 in 2024.

Technical Drivers

As of the 25th of April, Pacira Pharmaceuticals holds the Risk Adjusted Performance of (0.07), variance of 4.25, and Coefficient Of Variation of (862.62). Compared to fundamental indicators, the technical analysis model allows you to check existing technical drivers of Pacira Pharmaceuticals, as well as the relationship between them. Put it differently, you can use this information to find out if the company will indeed mirror its model of past market data, or the prices will eventually revert. We were able to interpolate data for thirteen technical drivers for Pacira Pharmaceuticals, which can be compared to its competitors. Please check Pacira Pharmaceuticals mean deviation and maximum drawdown to decide if Pacira Pharmaceuticals is priced some-what accurately, providing market reflects its current price of 25.9 per share. Given that Pacira Pharmaceuticals has information ratio of (0.16), we recommend you to check out Pacira Pharmaceuticals's recent market performance to make sure the company can sustain itself at a future point.

Pacira Pharmaceuticals Price Movement Analysis

Pacira Pharmaceuticals Insider Trading Activities

Pacira Pharmaceuticals Predictive Daily Indicators

Pacira Pharmaceuticals Corporate Filings

Pacira Pharmaceuticals Forecast Models

Pacira Pharmaceuticals' time-series forecasting models are one of many Pacira Pharmaceuticals' stock analysis techniques aimed at predicting future share value based on previously observed values. Time-series forecasting models ae widely used for non-stationary data. Non-stationary data are called the data whose statistical properties e.g. the mean and standard deviation are not constant over time but instead, these metrics vary over time. These non-stationary Pacira Pharmaceuticals' historical data is usually called time-series. Some empirical experimentation suggests that the statistical forecasting models outperform the models based exclusively on fundamental analysis to predict the direction of the market movement and maximize returns from investment trading.

Stock analysis is the technique used by a trader or investor to examine and evaluate how Pacira Pharmaceuticals prices is reacting to, or reflecting on a current market direction and economic conditions. It can be used to make informed decisions about market timing, and when buying or selling Pacira shares will generate the highest return on investment. We also built our stock analysis module to help investors to gain an insight into the world economy as a whole, the stock market, thematic ideas. a specific sector, or an individual Stock such as Pacira Pharmaceuticals. By using and applying Pacira Stock analysis, traders can create a robust methodology for identifying Pacira entry and exit points for their positions.

We track the performance of the top 100 financial experts across various large and mid-size financial boutiques. Pacira analyst recommendations are determined by taking all analyst recommendations and averaging them as Strong Buy, Buy, Hold, Strong Sell or Sell. There is no one specific way to measure analysis performance other than comparing it to the past results via a very sophisticated attribution analysis. Pacira analyst consensus and target price projections should be used in combination with other traditional techniques such as stock price forecasting, technical analysis, earnings estimate, and various momentum models.

Pacira Pharmaceuticals stock analysis indicators help investors evaluate how Pacira Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing and determine when trading Pacira Pharmaceuticals shares will generate the highest return on investment. By understating and applying Pacira Pharmaceuticals stock analysis, traders can identify Pacira Pharmaceuticals position entry and exit signals to maximize returns.

Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Pacira Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in metropolitan statistical area. For more information on how to buy Pacira Stock please use our How to Invest in Pacira Pharmaceuticals guide.You can also try the Performance Analysis module to check effects of mean-variance optimization against your current asset allocation.

When running Pacira Pharmaceuticals' price analysis, check to measure Pacira Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Pacira Pharmaceuticals is operating at the current time. Most of Pacira Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Pacira Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Pacira Pharmaceuticals' price. Additionally, you may evaluate how the addition of Pacira Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.

Is Pacira Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Pacira Pharmaceuticals. If investors know Pacira will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Pacira Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

The market value of Pacira Pharmaceuticals is measured differently than its book value, which is the value of Pacira that is recorded on the company's balance sheet. Investors also form their own opinion of Pacira Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Pacira Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Pacira Pharmaceuticals' market value can be influenced by many factors that don't directly affect Pacira Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Pacira Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Pacira Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Pacira Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.